Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today the launch of its Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg is the AB rated generic equivalent of Valeant Pharmaceuticals North America, LLC’s Wellbutrin XL® tablets, 150 mg and 300 mg. It is indicated for the treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder (SAD) in adults.

Wellbutrin XL® tablets had US sales of USD 758 million (IMS MAT May 2017).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 4^th and the 6^th largest generics pharmaceutical company by market capitalization (March 31^st, 2017, Bloomberg) and sales globally (December 31^st, 2016, Bloomberg). The Company is the 5^th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT Feb 2017); the 2^nd largest Indian pharmaceutical company by global revenues; the 6^th largest generic pharmaceutical player in Japan and the 4^th largest generic pharmaceutical company in South Africa (Quintiles IMS MAT March 2017).

For the financial year ended 31^st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3^rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055. 

For further information or queries please contact –

Arvind Bothra
Head – Investor Relations and M&A
Ph: +91-22-66402137
Email: arvindbothra@lupin.com

*Safe Harbor Statement

Wellbutrin XL® is a registered trademark of GlaxoSmithKline LLC used under license. ©Valeant Pharmaceuticals

North America LLC